Lidoderm Shows Promise in Treating Carpal Tunnel Syndrome

Susan Farley
Published Online: Sunday, January 1, 2006

A pilot study of Endo Pharmaceuticals' topical analgesic patch, lidocaine patch 5% (Lidoderm), showed a significant reduction in pain intensity, as well as a high satisfaction level among patients using the patch. Twenty patients treated with Lidoderm achieved a 41.5% reduction in mean pain intensity as measured by the Brief Pain Inventory. Another 20 patients received a single corticosteroid injection into the carpal tunnel and achieved a 43.8% reduction in pain intensity. Results also showed that 80% of patients treated with Lidoderm reported being "satisfied" or "very satisfied" with the treatment; investigators noted improvements in 88% of their patients. Among patients in the injection group, 59% reported being "satisfied" or "very satisfied" with their treatment, and investigators noted an overall 74% improvement in these patients. Study author Srinivas Nalamachu, MD, of the University of Medicine and Biosciences in Kansas City, Mo, commented, "We are excited to find a noninvasive, topical patch appeared to alleviate these patients' carpal-tunnel-syndrome-related pain." These results still need to be confirmed in a larger, double-blind, placebo-controlled study.

Ms. Farley is a freelance medical writer based in Wakefield, RI.

Latest Articles
In case you got caught up in the Thanksgiving holiday rush, here are the top trending stories you may have missed in November:
Bryan Ziegler, PharmD, executive director of Kennedy Pharmacy Innovation Center, provides some resources for community pharmacists to use when implementing new collaborative services with primary care providers.
James Schiffer, RPh, associate at Allegaert Berger & Vogel LLC, discusses some tips for pharmacists who are facing a Drug Enforcement Administration audit.
Carlos Aquino, founder and president of PharmaDiversion LLC, talks about the importance of the Drug Enforcement Administration's (DEA) diversion website.
Latest Issues